Trials / Recruiting
RecruitingNCT06947668
Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- University of Erlangen-Nürnberg Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Analysis of tumor tissue (which is already available in pathology) and collection of saliva/stool and blood samples, which are obtained as part of a routine collection. These will be evaluated together with the patients' clinical data to identify possible predictors for treatment feasibility, survival, tumor control and potentially increased tumor immunogenicity by docetaxel.
Conditions
- Squamous Cell Carcinoma of Oropharynx
- Squamous Cell Carcinoma of the Hypopharynx
- Larynx Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2030-06-01
- Completion
- 2030-12-31
- First posted
- 2025-04-27
- Last updated
- 2026-03-12
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06947668. Inclusion in this directory is not an endorsement.